Trulieve Announces Closing of $350 Million Private PlacementĀ of 8% Senior Secured Notes

Trulieve Cannabis Corp. ("Trulieve" or the "Company") (CSE: TRUL) (OTCQX: TCNNF) today announced that it has closed its previously announced private placement of 8% Senior Secured Notes due 2026 (the "Notes") for aggregate gross proceeds of US$350.0 million (the "Offering").

The Notes were issued at 100% of face value, are senior secured obligations of the Company and rank pari passu with the senior secured outstanding notes of the Company maturing in 2024. The Notes bear interest at a rate of 8% per annum, payable semi-annually in equal installments until the maturity date, unless earlier redeemed or repurchased. The Notes will mature on October 6, 2026, and may be redeemed in whole or in part, at any time from time to time, on or after October 6, 2023 at the applicable redemption price set forth in the supplemental indenture governing the Notes.

The Offering was conducted on a "best-efforts", private placement basis pursuant to the terms of an agency agreement between the Company and Canaccord Genuity Corp., as sole agent and sole bookrunner. The Company has made the required filings to list the Notes on the Canadian Securities Exchange (the "CSE") following the expiry of the four-month Canadian statutory hold period.

"Trulieve's strength in the capital markets provides us access to capital for strategic growth plans. Closing on the $350 million debt issuance, which we believe to be the largest debt financing to date of any public multi-state operator, combined with our cash position and continued cash flow from operations, has us well-positioned for our future goals in terms of expansion in key markets," stated Trulieve Chief Executive Officer, Kim Rivers . "At eight percent, this nondilutive financing carries exceptional terms and underscores Trulieve's industry-leading profitability and solid financial profile."

The Company intends to use the net proceeds of the Offering to redeem certain outstanding indebtedness of Harvest Health & Recreation Inc. ("Harvest") following the completion of the Company's acquisition of Harvest on October 1, 2021, and for capital expenditures and other general corporate purposes.

The offering and sale of the Notes have not been and will not be registered under the Securities ā€ŽAct of 1933, as amended (the "Securities Act"), or the laws of any other jurisdiction. This news release ā€Žshall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale ā€Žof the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful.

About Trulieve

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.

To learn more about Trulieve, visit www.Trulieve.com .

Forward-Looking Statements

This news release includes forward-looking information and statements, which may include, but ā€Žare not limited to, information and statements regarding or inferring the future business, ā€Žoperations, financial performance, prospects, and other plans, intentions, expectations, estimates, ā€Žand beliefs of the Company. Such statements include statements regarding the intended use of the net proceeds of the Offering, the listing of the Notes and other matters. Words such as "expects", ā€Žā€Ž"continue", "will", "anticipates" and "intends" or similar expressions are intended to identify ā€Žforward-looking statements. These forward-looking statements are based on the Company's ā€Žcurrent projections and expectations about future events and financial trends that management ā€Žbelieves might affect its financial condition, results of operations, business strategy and financial ā€Žneeds, and on certain assumptions and analysis made by the Company in light of the experience ā€Žand perception of historical trends, current conditions and expected future developments and ā€Žother factors management believes are appropriate. Forward-looking information and statements ā€Žinvolve and are subject to assumptions and known and unknown risks, uncertainties, and other ā€Žfactors which may cause actual events, results, performance, or achievements of the Company ā€Žto be materially different from future events, results, performance, and achievements expressed ā€Žor implied by forward-looking information and statements herein. Such factors include, among others: risks and uncertainties relating to the actual use of the net proceeds of the Offering; risks related to the effect of the COVID-19 pandemic on the global economy, financial markets and the Company's business; and the risks discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 and in subsequent periodic and current reports filed with the United States Securities and Exchange Commission and in the Company's filings on SEDAR at www.sedar.com .

Although the Company ā€Žbelieves that any forward-looking information and statements herein are reasonable, in light of ā€Žthe use of assumptions and the significant risks and uncertainties inherent in such information ā€Žand statements, there can be no assurance that any such forward-looking information and ā€Žstatements will prove to be accurate, and accordingly readers are advised to rely on their own ā€Ževaluation of such risks and uncertainties and should not place undue reliance upon such ā€Žforward-looking information and statements. Any forward-looking information and statements ā€Žherein are made as of the date hereof, and except as required by applicable laws, the Company ā€Žassumes no obligation and disclaims any intention to update or revise any forward-looking ā€Žinformation and statements herein or to update the reasons that actual events or results could or ā€Ždo differ from those projected in any forward looking information and statements herein, whether ā€Žas a result of new information, future events or results, or otherwise, except as required by ā€Žapplicable laws.ā€Ž

The CSE has not reviewed, approved or disapproved the ā€Žcontent of this news release.ā€Ž

For further information:

Lynn Ricci, Director of Investor Relations, 1-850-270-5691, lynn.ricci@trulieve.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

Trulieve to Open Medical Cannabis Dispensary in Columbus, Georgia

New Muscogee County location will host grand opening celebration Friday, December 20 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF )Ā Ā ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new medical cannabis dispensary in Columbus, Georgia .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Tampa, Florida

New Hillsborough County location will host grand opening celebration Friday December 13

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S.,Ā today announced the opening of a new medical cannabis dispensary in Tampa, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: DEA Postpones Rescheduling Hearing, Key Players Share Quarterly Results

November was a busy month for the cannabis industry, with a slew of US-centric developments.

A hearing on cannabis rescheduling was postponed until 2025, although the incoming Trump administration has signaled its intent to follow through on the change despite opposition from some Republican lawmakers.

Meanwhile, several states voted on cannabis measures, and companies reported their latest quarterly results.

Keep reading...Show less
Cannabis plants and a stock chart.

US Cannabis Sales Hit Record in October, Market Set to Reach US$55 Billion by 2030

Cannabis sales in the US reached a record high in October, with retail transactions totaling approximately US$2.8 billion, according to data from LeafLink, a wholesale cannabis platform.

While sales saw a slight 2.1 percent dip compared to September, they were up 6.2 percent year-on-year. Total retail cannabis sales in 2024 are expected to hit US$32.6 billion, representing a 10.8 percent increase over the previous year.

LeafLink attributes much of this growth to new licenses in states such as New York, New Jersey and Ohio.

Keep reading...Show less
Australia flag and cannabis.

Australian Senate Rejects Greens' Bill to Legalise Cannabis

The Australian Greens announced on Wednesday, November 27, that the Legalising Cannabis Bill 2023 was defeated in a 13 to 24 vote, preventing the federal legalisation of cannabis.

ā€œThe Labor and Coalition parties joined together to try and hold Australia back in the 1950s by blocking this desperately needed reform,ā€ said Greens Senator for New South Wales David Shoebridge.

Shoebridge said on X that the parties ā€œteamed upā€ to vote against legalizing cannabis in the Senate, ā€œyet another example of the major parties working together to refuse any sort of progress.ā€

All 11 Greens Senators voted in favour of the Bill, as did Independent Senators Lidia Thorpe and Tammy Tyrrell.

Keep reading...Show less
Cannabis and Australian money.

Victoria Amends Driving Rules for Medicinal Cannabis Users, Changes Effective in Mid-2025

Both houses of parliament in Victoria, Australia, have successfully passed the Roads and Road Safety Legislation Amendment Bill 2024, Cannabis Council Australia said in a recent newsletter.

The organisation sees this as a ā€œpromising developmentā€ in the area, calling it a ā€œcritical legislative milestone." The bill's passing will allow for judicial discretion when decisions about medicinal cannabis are made.

Magistrates will now have the ability to evaluate individual cases where drivers who hold valid medicinal cannabis prescriptions test positive for THC, but show no signs of impairment.

Keep reading...Show less

Latest Press Releases

Related News

Ɨ